LENSAR Q1 revenue falls 5%, hurt by merger uncertainty; recurring revenue rises 9%

LENSAR

08/05/2026 12:15

Overview

US robotic cataract laser maker's Q1 revenue fell 5% yr/yr due to terminated Alcon deal

Q1 recurring revenue rose 9% and made up 94% of total revenue

Company posted net income after prior-year loss, driven by merger termination and warrant gains

Outlook

Company expects recurring revenue to grow as utilization increases and system placements normalize

LENSAR says underlying business fundamentals remain strong following merger-related disruption

Result Drivers

MERGER UNCERTAINTY - Co said Q1 system sales and total revenue fell due to market disruption and uncertainty around the now-terminated Alcon merger

RECURRING REVENUE GROWTH - Q1 recurring revenue rose 9% yr/yr, driven by higher procedure volume

INSTALLED BASE EXPANSION - Total installed base of ALLY and LENSAR systems grew 12% yr/yr, with 7 ALLY placements and 11 systems in backlog

Company press release: ID:nGNX3x82Tp

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
$36.3 mln
Q1 EBITDA
$37.3 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for LENSAR Inc is $8.50, about 62.5% above its May 7 closing price of $5.23

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)